Launched in 2005, NAF’s biennial Ataxia Investigators Meeting (AIM) brings together world-leading Ataxia clinicians and scientists who are working to accelerate the pace of Ataxia research, better understand the disease, and develop therapies.

AIM 2020: Leveraging Therapeutic Opportunity into Novel Treatment Paradigms, will be held on March 3-6, 2020 at the Sheraton Denver Downtown. This meeting will address 5 themes:

1. Cerebellar function and dysfunction.
2. Neuroprotective targets and strategies.
3. Disease modeling and mechanisms.
4. Emerging therapeutic modalities and biomarker discovery.
5. Clinical trial organization.

The meeting chair is Dr. Al La Spada at Duke University and co-chair is Dr. Stephan Pulst at University of Utah.

Details on abstract submission for AIM 2020 will be posted on September 9, 2019. The deadline for submission of abstracts is November 8, 2019.  Selected abstracts will be announced on December 13, 2019.

Early career Ataxia researchers, women, and underrepresented minorities are encouraged to submit abstracts.

To be included on the AIM 2020 email list, contact Sue Hagen at susan@ataxia.org.

Sponsorship support for 2018 AIM provided by: